The effect of intracavernosal growth differentiation factor-5 therapy in a rat model of cavernosal nerve injury

BJU International

Volumn 98, Issue 3, 2006, Pages 632-636

  Fandel, Thomas M ^a   Bella, Anthony J ^a   Tantiwongse, Kavirach ^a   Garcia, Maurice ^a   Nunes, Lora ^a   Thüroff, Joachim W ^b   Tanagho, Emil A ^a   Pohl, Jens ^c   Lue, Tom F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Biopharm GmbH   (Germany)

Author keywords

Erectile dysfunction; Growth differentiation factor 5; Neurogenic impotence

Indexed keywords

COLLAGEN; GROWTH DIFFERENTIATION FACTOR 5; NEURONAL NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAVERNOUS NERVE INJURY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; ELECTROSTIMULATION; HISTOCHEMISTRY; HISTOLOGY; MALE; NERVE FIBER; NERVE INJURY; NERVE STIMULATION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; BONE MORPHOGENETIC PROTEINS; IMPOTENCE; MALE; NERVE REGENERATION; PENIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TRAUMA, NERVOUS SYSTEM;

EID: 33746891485     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06375.x     Document Type: Article

References (27)

1. American Cancer Society. Cancer facts & figures 2006. Atlanta, GA. American Cancer Society 2006. Available at: http://www.cancer.org/docroot/STT/ stt_0.asp. Accessed May 2006
2. Graefen M, Walz J, Huland H. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006; 49: 38-48
3. Lepor H. Radical prostatectomy: status and opportunities for improving outcomes. Cancer Invest 2004; 22: 435-44
4. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128: 492-7
5. Walsh PC, Mostwin JL. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol 1984; 56: 694-7
6. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA 2005; 293: 2648-53
7. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ('trifecta'). Urology 2005; 66 (Suppl. 5): 83-94
8. Burnett MG, Zager EL. Pathophysiology of peripheral nerve injury: a brief review. Neurosurg Focus 2004; 16: E1
9. Hall S. The response to injury in the peripheral nervous system. J Bone Joint Surg Br 2005; 87: 1309-19
10. Frostick SP, Yin Q, Kemp GJ. Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery 1998; 18: 397-405
11. Hsieh PS, Bochinski DJ, Lin GT, Nunes L, Lin CS, Lue TF. The effect of vascular endothelial growth factor and brain-derived neurotrophic factor on cavernosal nerve regeneration in a nerve-crush rat model. BJU Int 2003; 92: 470-5
12. Chen KC, Minor TX, Rahman NU, Ho HC, Nunes L, Lue TF. The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence. BJU Int 2005; 95: 1077-80
13. Hötten G, Neidhardt H, Jacobowsky B, Pohl J. Cloning and expression of recombinant human growth/differentiation factor 5. Biochem Biophys Res Commun 1994; 204: 646-52
14. Krieglstein K, Suter-Crazzolara C, Hötten G, Pohl J, Unsicker K. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. J Neurosci Res 1995; 42: 724-32
15. Sullivan AM, O'Keeffe GW. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment. J Anat 2005; 207: 219-26
16. Farkas LM, Scheuermann S, Pohl J, Unsicker K, Krieglstein K. Characterization of growth/differentiation factor 5 (GDF-5) as a neurotrophic factor for cultured neurons from chicken dorsal root ganglia. Neurosci Lett 1997; 236: 120-2
17. Carrier S, Zvara P, Nunes L, Kour NW, Rehman J, Lue TF. Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol 1995; 153: 1722-7
18. Quinlan DM, Nelson RJ, Walsh PC. Cavernous nerve grafts restore erectile function in denervated rats. J Urol 1991; 145: 380-3
19. Bakircioglu ME, Lin CS, Fan P, Sievert KD, Kan YW, Lue TF. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol 2001; 165: 2103-9
20. Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7: 1073-4
21. Bochinski D, Lin GT, Nunes L et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int 2004; 94: 904-9
22. Lehrfeld TJ, Lagoda G, Burnett AL. An early course of sildenafil and FK506 treatment on erectile function after cavernous nerve injury. J Sex Med 2006; 3 (Suppl. 1): 41, Abstract 85
23. Gholami SS, Rogers R, Chang J et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol 2003; 169: 1577-81
24. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001; 24: 677-736
25. Storm EE, Huynh TV, Copeland NG, Jenkins NA, Kingsley DM, Lee SJ. Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily. Nature 1994; 368: 639-43
26. Nishitoh H, Ichijo H, Kimura M et al. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 1996; 271: 21345-52
27. Niere M, Braun B, Gass R, Sturany S, Volkmer H. Combination of engineered neural cell adhesion molecules and GDF-5 for improved neurite extension in nerve guide concepts. Biomaterials 2006; 27: 3432-40